Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 21, 2019 09:00 ET | Source: Kalytera Therapeutics Inc.

Kalytera Announces Engagement of Echelon Wealth Partners to Assist with Review of Potential Out-License Opportunities for Commercial Rights to GVHD Products

SAN FRANCISCO and TEL AVIV, Israel, May 21, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") has engaged Echelon Wealth Partners...
March 22, 2019 07:30 ET | Source: Kalytera Therapeutics Inc.

Kalytera Reports Data for First Cohort in Phase 2 Clinical Study Evaluating CBD in Prevention of Acute GVHD

SAN FRANCISCO and TEL AVIV, Israel, March 22, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced positive data...
March 06, 2019 07:30 ET | Source: Kalytera Therapeutics Inc.

Kalytera Announces Initiation of Study KAL-07 – Food Effect Study

SAN FRANCISCO and TEL AVIV, Israel, March 06, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has...
February 05, 2019 07:30 ET | Source: Kalytera Therapeutics Inc.

Kalytera Reports Additional Positive Data for CBD in Prevention of Acute GVHD

SAN FRANCISCO and TEL AVIV, Israel, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced additional...
January 15, 2019 07:30 ET | Source: Kalytera Therapeutics Inc.

Kalytera Announces Initiation of Research Coverage by Echelon Wealth Partners

SAN FRANCISCO and TEL AVIV, Israel, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") announced that Echelon Wealth...
December 20, 2018 12:10 ET | Source: Kalytera Therapeutics Inc.

Kalytera Provides Update on Phase 2 Clinical Study Evaluating CBD in Prevention of Acute GVHD

SAN FRANCISCO and TEL AVIV, Israel, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced positive interim...
September 27, 2018 07:30 ET | Source: Kalytera Therapeutics Inc.

Kalytera Announces Progress with Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain

SAN FRANCISCO and TEL AVIV, Israel, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced a major step...
September 20, 2018 07:30 ET | Source: Kalytera Therapeutics Inc.

Kalytera Therapeutics Provides Update for Lead Program in Prevention and Treatment of GVHD

SAN FRANCISCO and TEL AVIV, Israel, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today provided an update on its...
August 30, 2018 07:30 ET | Source: Kalytera Therapeutics Inc.

Kalytera Reports Second Quarter 2018 Financial Results

SAN FRANCISCO and TEL AVIV, Israel, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today reported financial results...
August 02, 2018 08:00 ET | Source: Kalytera Therapeutics Inc.

Kalytera Completes Pre-IND Meeting with FDA

SAN FRANCISCO, Calif. and TEL AVIV, Israel, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it...